# POTASSIUM HOMEOSTASIS

**Overview** (_NEJM_ 2015;373:60)

• Renal: K excretion regulated at **distal nephron** (CCD) by principal & α-intercalated cells

Distal Na delivery & urine flow: Na absorption → lumen electronegative → K secretion

Metabolic alkalemia and aldosterone: increase Na absorption and K secretion

nb, diurnal urinary K excretion (day > night), ∴ 24-h sample preferred over spot

• Transcellular shifts: most common cause of acute ∆ in serum K (98% intracellular)

Acid-base disturbance: K+/H+ exchange across cell membranes

Insulin → stimulates Na-K ATPase → hypokalemia (mitigates postprandial ↑ K)

Catecholamines → stimulate Na-K ATPase → hypokalemia; reversed by β-blockers

Massive necrosis (eg, tumor lysis, rhabdo, ischemic bowel) → release of intracellular K

Hypo- or hyperkalemic periodic paralysis: rare disorders due to channel mutations

• Diet: alone rarely causes ↑ or ↓ K (total body store ~3500 mEq, daily intake ~100 mEq)

# HYPOKALEMIA

## Transcellular shifts
> (UK:Cr <13 mEq/g)

• Alkalemia, insulin, catecholamines, β2\-agonists, hypothermia, hypokalemic/thyrotoxic periodic paralysis, acute ↑ hematopoiesis (megaloblastic anemia Rx w/ B12, AML crisis), chloroquine; overdose: Ba/Cs, antipsychotics (risperidone, quetiapine), theophylline

## GI potassium losses
> (UK:Cr <13 mEq/g)

• GI losses _plus_ metabolic acidosis: diarrhea, laxative abuse, villous adenoma

• Vomiting & NGT drainage usually manifest as _renal losses_ due to 2° hyperaldo & met. alk.

## Renal potassium losses
> (UK:Cr >13 mEq/g)

• Hypotensive or normotensive

acidosis: DKA, RTA \[proximal RTA (type II) and some distal RTAs (type I)\]

alkalosis: diuretics (thiazide > loop), vomiting/NGT drainage (via 2° hyperaldosteronism)

Bartter’s syndrome (loop of Henle dysfxn→ furosemide-like effect; _JASN_ 2017;28:2540)

Gitelman’s syndrome (DCT dysfxn→ thiazide-like effect (_KI_ 2017;91:24)

drugs: ↑↑ acetaminophen & PCN, gent., amphotericin, foscarnet, cisplatin, ifosfamide

↓ Mg: less Mg to inhibit principal cell ROMK channel, ∴ ↑ K secretion (_JASN_ 2010;21:2109)

• Hypertensive: mineralocorticoid excess

1° hyperaldosteronism (eg, Conn’s syndrome, glucocorticoid-remediable aldosteronism)

2° hyperaldosteronism (eg, renovascular disease, renin-secreting tumor)

Nonaldosterone mineralocorticoid (eg, Cushing’s, Liddle’s \[↑ ENaC\], exogenous, licorice)

## Clinical manifestations

• Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, ↓ insulin secretion

• Renal: ammoniagenesis, phosphaturia, hypocitraturia, NaCl & HCO3 retention, polyuria

• ECG: may see U waves, ↑ QT, flat Tw, ST depression, ventricular ectopy (PVCs, VT, VF)

## Workup
> (_Nat Rev Nephrol_ 2011;7:75)

• Identify transcellular shifts & treat. TTKG validity questioned (_Curr Op Nephro_ 2011;20:547).

• ✔ **U****K:Cr**: >13 mEq/g → renal loss; <13 mEq/g → extrarenal loss (_Archives_ 2004;164:1561)

• If renal losses, ✔ **BP**, **acid-base**, **UCl** (UNa unreliable), UCa/Cr, renin, aldosterone, cortisol

**Figure 4-7** Approach to hypokalemia

![](images/00073.jpeg)

## Treatment
> (_JAMA_ 2000;160:2429)

• _If true potassium deficit:_ **potassium repletion** (↓ 1 mEq/L ≈ 200 mEq total body loss)

Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1L IVF

• Replete K+ to >3 or >4 mEq/L if high-risk (HTN, CHF, arrhythmias, MI, digoxin, cirrhosis)

• Beware of excessive potassium repletion if transcellular shift cause of hypokalemia

• Treat underlying cause (if ↓ vol: avoid dextrose as ↑ insulin → intracellular potassium shifts)

• Consider Rx that ↓ K loss: ACEI/ARB, K+\-sparing diuretics, βB

• Replete Mg if <2 mEq/L: IV Mg-SO4 1–2 g q2h (oral Mg-oxide poorly tolerated b/c diarrhea)

Causes of low Mg: GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI); renal loss (diuretics, nephrotoxic drugs, EtOH, ↑ Ca, 1° wasting syndromes, volume expansion)

# HYPERKALEMIA

## Transcellular shifts
> (_BMJ_ 2009;339:1019)

• Acidemia, ↓ insulin (DM), cell lysis (tumor, rhabdo, ischemic bowel, hemolysis, transfusions, resorbing hematomas, hyperthermia, rewarming), hyperkalemic periodic paralysis, ↑ osmolality. Drugs: succinylcholine, aminocaproic acid, digoxin, β-blockers.

## Decreased GFR

• Any cause of oliguric or anuric AKI or any cause of end-stage renal disease

**Normal GFR but with** ↓ **renal K excretion**

• Normal aldosterone function

↓ EAV (K excretion limited by ↓ **distal Na delivery & urine flow**): CHF, cirrhosis

Excessive K intake: in conjunction with impairment in K excretion or transcellular shift

Ureterojejunostomy (absorption of urinary K in jejunum)

• **Hypoaldosteronism:** same as etiologies of hypoaldo RTA (type IV)

↓ renin: DM, NSAIDs, chronic interstitial nephritis, HIV, multiple myeloma, Gordon’s

Normal renin, ↓ aldo synthesis: 1° adrenal disorders, ACEI, ARBs, heparin, ketoconazole

↓ response to aldosterone Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors Tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes

## Clinical manifestations

• Weakness, nausea, paresthesias, palpitations; Renal: ↓ NH4+ secretion → acidosis

• ECG: ST depression, peaked T waves, ↓ QT, ↑ PR interval, ↑ QRS width, loss of P wave, sine wave pattern, PEA/VF (ECG: low sens., cardiac arrest can be first manifestation!)

## Workup
> (_Crit Care Med_ 2008;36:3246)

• Rule out pseudohyperkalemia (IVF w/ K, tourniquet, hemolysis, ↑ plt or WBC), rule out transcellular shift

• **Assess GFR**, if normal, then ✔UK, UNa (<25 mEq/d ↓ distal Na delivery). ✔ UK:Cr (<13 favors ↓ renal K excretion).

![](images/00074.jpeg)

aCaCl contains more calcium and is typically reserved for codes (↑ risk of tissue necrosis) or via central line

b~0.4% intestinal necrosis esp. postop, ileus, SBO/LBO, bowel disease (UC), renal txp (_Clin Nephro_ 2016;85:38)

• _Rate of onset_ important to note when establishing a treatment plan

• **Stabilize** (initial): 10% CaCl (central) or gluconate (IV). ↑ memb. potential → ↓ excitability

• **Redistribute**: insulin + dextrose (continuous if NPO), HCO3 (_KI_ 1991;41:369), β2\-agonists

• **Eliminate**: SPS (Kayexalate, _NEJM_ 2015;372:211), patiromer (expensive), diuretics (w/ saline if preserved renal fxn), consider emergent HD in life-threatening situations

• Patient information for diet education: [http://www.kidney.org/atoz/content/potassium](http://www.kidney.org/atoz/content/potassium)
